世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

馬脳炎:パイプラインレビュー 2016年下半期

Equine Encephalitis - Pipeline Review, H2 2016

 

出版社 出版年月電子版価格 ページ数
Global Markets Direct
グローバルマーケッツダイレクト社
2016年10月US$2,000
シングルユーザライセンス
51

サマリー

Global Markets Directによる馬脳炎のパイプラインレビューです。



Report Details

Equine Encephalitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides an overview of the Equine Encephalitis (Central Nervous System) pipeline landscape.

Equine encephalitis (EE) is mosquito transmitted disease that can cause severe inflammation of the brain (encephalitis) in humans. Symptoms include the sudden onset of fever, chills, body and joint aches. Infection can develop into severe encephalitis, resulting in headache, disorientation, tremors, seizures and paralysis. Permanent brain damage, coma and death may also occur in some cases. Approximately a third of patients who develop EE die, and many of those who survive have mild to severe brain damage.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Equine Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Equine Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 8 and 3 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 1 molecules, respectively for Equine Encephalitis.

Equine Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Equine Encephalitis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Equine Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Equine Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Equine Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Equine Encephalitis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Equine Encephalitis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Equine Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

目次

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Equine Encephalitis Overview 7
Therapeutics Development 8
Pipeline Products for Equine Encephalitis - Overview 8
Pipeline Products for Equine Encephalitis - Comparative Analysis 9
Equine Encephalitis - Therapeutics under Development by Companies 10
Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes 11
Equine Encephalitis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Equine Encephalitis - Products under Development by Companies 14
Equine Encephalitis - Products under Investigation by Universities/Institutes 15
Equine Encephalitis - Companies Involved in Therapeutics Development 16
Akshaya Bio Inc. 16
Altravax, Inc. 17
EpiVax, Inc. 18
Integrated BioTherapeutics, Inc. 19
Karyopharm Therapeutics, Inc. 20
Profectus BioSciences, Inc. 21
Equine Encephalitis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
DEF-201 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
equine encephalitis vaccine - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
equine encephalitis vaccine - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
equine encephalitis vaccine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
imatinib mesylate - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Monoclonal Antibody for Venezuelan Equine Encephalitis - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
nilotinib - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
TSI-GSD-104 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Vaccine for Western Equine Encephalitis - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
venezuelan equine encephalitis vaccine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Venezuelan equine encephalitis vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
venezuelan equine encephalitis vaccine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
verdinexor - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Westrern Equine Encephalitis Virus Vaccine - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Equine Encephalitis - Dormant Projects 47
Equine Encephalitis - Product Development Milestones 48
Featured News & Press Releases 48
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses 48
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る